CSPC Pharmaceutical Group Limited (CSPCY)
OTCMKTS
· Delayed Price · Currency is USD
4.120
+0.085 (2.11%)
Jul 9, 2025, 3:53 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Vitamin C | 1.99B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vitamin C Growth | 13.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics | 1.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics Growth | -5.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others | 1.69B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others Growth | -19.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nervous System | 9.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nervous System Growth | -8.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology | 4.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Growth | -47.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Anti-Infectives | 4.09B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Anti-Infectives Growth | -16.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular | 2.08B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular Growth | -31.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory System | 1.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory System Growth | -30.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Digestion and Metabolism | 1.05B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Digestion and Metabolism Growth | 2.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Therapeutic Areas | 1.26B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Therapeutic Areas Growth | -7.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Licence Fee Income | 17.83M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Licence Fee Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Finished Drugs Segment Profit | 4.83B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Finished Drugs Segment Profit Growth | -37.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vitamin C Segment Profit | 211.28M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vitamin C Segment Profit Growth | -2239.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics Segment Profit | 299.18M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics Segment Profit Growth | 21.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others Segment Profit | 305.29M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others Segment Profit Growth | -50.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -277.18M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | -22.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Mainland China | 25.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Mainland China Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Asian Regions | 1.18B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Asian Regions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Americas | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Americas Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 1.31B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Revenue (Pre-FY2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Revenue (Pre-FY2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America | 853.04M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies | 553.88M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|